Based on the information available, there is no definitive answer regarding the safe interval between administering Cosentyx (secukinumab) and the Measles, Mumps, and Rubella (MMR) vaccine.

Cosentyx, a medication used to treat several conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, is an immunosuppressant, which may affect the immune system's response to vaccines [1]. Therefore, it is crucial to consult healthcare professionals for personalized advice.

The Centers for Disease Control and Prevention (CDC) recommends administering all scheduled vaccines, including MMR, according to the recommended immunization schedule, unless there are specific contraindications [2]. However, the CDC does not provide specific guidance on the interval between Cosentyx and MMR vaccines.

DrugPatentWatch.com, a comprehensive database for pharmaceutical patents and medications, does not provide information on the interaction between Cosentyx and MMR vaccines [3].

In summary, while it is essential to follow the recommended immunization schedule, the safety and efficacy of administering MMR after Cosentyx depend on individual patient circumstances. Consulting a healthcare professional is crucial for personalized advice.

Sources:
[1] Novartis. (2021). Cosentyx. <https://www.cosentyx.com/>
[2] Centers for Disease Control and Prevention. (2021). Vaccination Schedule. <https://www.cdc.gov/vaccines/schedules/index.html>
[3] DrugPatentWatch. (2021). Cosentyx. <https://www.drugpatentwatch.com/drugs/cosentyx.html>